🇺🇸 FDA
Company

Legend

Legend Biotech Corp

LEGN biotech USA

Quick answer

Legend is a biotech company (LEGN) headquartered in SOMERSET, NJ, USA with 24 tracked pipeline programs.

Pipeline (24)

project

LCAR-B38M CAR-T Cell

Multiple Myeloma

Phase 2 · mab · terminated

1 trials project

LCAR-B38M CAR-T cell injection

Refractory or Relapsed Multiple Myeloma

Phase 2 · mab · active

1 trials project

CAR-T Re-treatment

Multiple Myeloma

Phase 1 · small_molecule · active

1 trials project

CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

Relapsed/Refractory B-cell Malignancies

Phase 1 · mab · active

1 trials project

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

Refractory B Acute Lymphoblastic Leukemia

Phase 1 · small_molecule · terminated

1 trials project

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

Lymphoma, B-Cell

Phase 1 · small_molecule · terminated

1 trials project

Efficacy of LCAR-T2C CAR-T cells

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

Phase 1 · small_molecule · terminated

1 trials project

Efficacy of LCAR-T2C CAR-T cells

T Cell Lymphoma

Phase 1 · small_molecule · terminated

1 trials project

LB1901

T-Cell Lymphoma

Phase 1 · mab · active

1 trials project

LB1908

Gastric Cancer

Phase 1 · mab · active

1 trials project

LB2102

Small Cell Lung Cancer Extensive Stage

Phase 1 · mab · active

1 trials project

LCAR-AIO T cells

Systemic Lupus Erythematosus (SLE)

Phase 1 · mab · active

1 trials project

LCAR-AIO T cells

Multiple Sclerosis (MS)

Phase 1 · mab · active

1 trials project

LCAR-AIO T cells

Relapsed/Refractory Autoimmune Diseases

Phase 1 · mab · terminated

1 trials project

LCAR-AIO cells product

B-cell Lymphoma Recurrent

Phase 1 · mab · terminated

1 trials project

LCAR-AMDR Cells Product

Acute Myeloid Leukemia

Phase 1 · mab · terminated

1 trials project

LCAR-B4822M CAR-T Cell Immunotherapy

Refractory or Relapsed Multiple Myeloma

Phase 1 · small_molecule · active

1 trials project

LCAR-BCDR cells product

Relapsed/Refractory Multiple Myeloma

Phase 1 · mab · terminated

1 trials project

LCAR-BCX cells product

Relapsed/Refractory Multiple Myeloma

Phase 1 · mab · active

1 trials project

LCAR-C182A cells

Gastric Cancer

Phase 1 · mab · terminated

1 trials project

LCAR-C18S cells

Solid Tumors, Adult

Phase 1 · mab · terminated

1 trials project

LCAR-G08 cells

Advanced Gastrointestinal Tumors

Phase 1 · mab · terminated

1 trials project

LCAR-HL30 cells

Hodgkin's Lymphoma

Phase 1 · mab · active

1 trials project

LCAR-M23 cells

Epithelial Ovarian Cancer

Phase 1 · mab · terminated

1 trials

Patents (8)

patent

US 12421292

Anti-DLL3 chimeric antigen receptors and uses thereof

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12351638

Chimeric antigen receptors targeting BCMA and methods of use thereof

Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12275788

Single-domain antibodies against CD33 and constructs thereof

Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12258418

Claudin18.2 binding moieties and uses thereof

Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12240914

Antibody against factor XIa in activated form of coagulant factor XI, preparatio

Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12168688

Antibodies and variants thereof against PD-L1

Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12097219

Single-domain antibodies against CLL1 and constructs thereof

Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12006363

Anti-tetraspanin 33 agents and compositions and methods for making and using the

Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)